SCHEMBL989437

SCHEMBL989437

COC(=O)c1cc(-c2ccccc2)cn1Cc1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.49
CDK8 P49336 1/20 0.49
MAPT P10636 5/20 0.48
PTGS2 P35354 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
DRD2 P14416 1/20 0.42
TBXA2R P21731 1/20 0.42
RAB9A P51151 1/20 0.42
THRB P10828 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
P2RX3 P56373 1/20 0.41
MAPK8 P45983 1/20 0.41
AR P10275 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12584500 0.85 CCNC (0.54) CCNCCDK8MAPTMEN1KMT2A
SCHEMBL5450881 0.84 CNR1 (0.51) MAPTSLC6A4SLC6A3P2RX3MAPK8
SCHEMBL16116241 0.84 CCNC (0.71) CCNCCDK8MAPTMAPK1THRB
SCHEMBL12584531 0.81 CYP1A2 (0.47) MEN1KMT2ACYP1A2CYP2C9THRB
SCHEMBL988302 0.80 MAPT (0.49) MAPTPTGS2MEN1KMT2ARAB9A
SCHEMBL1126922 0.80 MAPT (0.43) CCNCCDK8MAPTMEN1KMT2A
SCHEMBL30287981 0.77 KIF11 (0.52) CCNCCDK8MAPTMEN1KMT2A
SCHEMBL16862475 0.77 KIF11 (0.52) CCNCCDK8MAPTMEN1KMT2A
SCHEMBL28187100 0.76 MAPT (0.48) MAPTMEN1KMT2ACYP1A2THRB
SCHEMBL16115854 0.76 ADRA1D (0.51) MAPTMEN1KMT2ACYP1A2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed
WO-2009139373-A1 AMIDE COMPOUND アステラス製薬株式会社 (JP) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 CCNC 1419/4885CDK8 658/4885MAPT 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.